Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria
- 1 July 2018
- journal article
- letter
- Published by Elsevier BV in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (4), 1386-1388.e1
- https://doi.org/10.1016/j.jaip.2017.10.030
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their changeAllergy, 2017
- Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2015
- Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticariaJournal of Allergy and Clinical Immunology, 2015
- Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysisJournal of Dermatological Science, 2014
- Retrospective analysis of the efficacy of omalizumab in chronic refractory urticariaAllergy and Asthma Proceedings, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?PLOS ONE, 2011
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004